Highlights

  • Racura Oncology Limited (ASX: RAC) lodged an Appendix 3H on 13 July 2026 notifying the cessation of 270,000 options coded RACAL following their expiry.
  • The options, described as "OPTION EXPIRING 12-JUL-2026 EX $4.76", ceased on 12 July 2026 without being exercised or converted, and no consideration was paid by the company.
  • Because the options were never exercised, no new shares were issued, so the ordinary share count was not materially changed by this event.
  • Following the change, Racura Oncology reports 196,068,940 ordinary fully paid shares on issue, while the RACAL line now shows zero
  • This is a routine administrative and capital-structure housekeeping update, not evidence of improving business performance for ASX: RAC.

Corporate announcements from clinical-stage biotechnology companies are not all created equal. Some report clinical milestones, capital raisings or partnership deals, while others are purely administrative filings that keep a company's records compliant with ASX rules. The latest lodgement from Racura Oncology Limited (ASX: RAC) belongs firmly in the second category. On 13 July 2026, the company lodged an Appendix 3H notifying the market that 270,000 options had ceased to exist following their expiry.

For investors, the short answer is that very little has changed at an operational level. No cash was raised, no new shares were created, and the company's underlying pipeline of cancer therapies was unaffected. This article explains what an Appendix 3H is, what the expiry of these options involved, and why Racura Oncology and its ASX: RAC listing are essentially unchanged by the event.

Inside the Announcement

The document Racura Oncology lodged is an Appendix 3H, the standard ASX form titled "Notification of cessation of securities". Listed companies use this form whenever securities such as options or performance rights stop being on issue, recording how many ceased, under what code, for what reason, and whether any payment changed hands.

In this case, the securities that ceased were 270,000 options carrying the code RACAL. The ASX description of these options was "OPTION EXPIRING 12-JUL-2026 EX $4.76", which tells you two things at a glance. First, the options had a fixed expiry date of 12 July 2026. Second, they carried an exercise price of $4.76, meaning the holder would have needed to pay $4.76 per option to convert each one into an ordinary share.

The reason recorded for the cessation was expiry without exercise or conversion, with the date of cessation listed as 12 July 2026. In plain terms, the holders simply let the options lapse rather than paying the exercise price to convert them into shares. The Appendix 3H also confirms that no consideration was paid by the entity for the cessation; the options expired naturally under their own terms.

Following the change, the issued capital table shows 196,068,940 ordinary fully paid shares on issue under the RAC ordinary fully paid line, while the RACAL option line now shows a balance of zero. The company also retains a number of other unquoted option classes on issue, so this filing addressed only one parcel rather than the whole options register.

Background: Racura Oncology and RC220

Racura Oncology Limited describes itself as a Phase 3 clinical-stage biopharmaceutical company with a mission to "silence cancer". Its lead asset is (E,E)-bisantrene, a small molecule anticancer agent that primarily acts through G-quadruplex (G4) DNA and RNA binding, leading to potent silencing of MYC (c-MYC), an important regulator of cancer growth. The company has stated that (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients and carries a well-characterised safety profile. RC220 is a proprietary formulation of (E,E)-bisantrene.

The company is advancing three clinical programs. The first is a Phase 3 program in acute myeloid leukaemia (AML) using RC220 to target c-MYC silencing. The second is HARNESS-1, a Phase 1a/b trial of RC220 combined with Tagrisso (osimertinib) in mutant EGFR (EGFRm) non-small cell lung cancer (NSCLC). The third is CPACS, a Phase 1a/b program combining RC220 with doxorubicin in solid tumours, aiming to deliver both cardioprotection and enhanced anticancer activity. The company has also said its recent discoveries enabled composition-of-matter intellectual property filings that may provide up to 20 years of patent protection over (E,E)-bisantrene, and that it is actively exploring partnerships, licences and merger and acquisition opportunities to accelerate access to RC220.

None of these programs are affected by the options expiry. The Appendix 3H concerns only the company's capital structure, and this background is offered purely to explain the business behind the ASX: RAC ticker.

Why an Options Expiry Is Capital-Structure Housekeeping

What options are and why they lapse

An option is a right, but not an obligation, to buy a share at a fixed price, known as the exercise price, on or before a set date. Companies commonly issue options to employees, advisers, brokers or investors as incentives or as part of financing arrangements. An option only has value if it is worthwhile to pay the exercise price to acquire a share. When it reaches its expiry date and the holder has chosen not to exercise, the option simply ceases to exist, which is exactly what happened with the 270,000 RACAL options.

The two things that did not happen

Two points are central to understanding this event correctly. First, the expiry did not generate any cash for Racura Oncology. Cash would only have flowed to the company if holders had exercised their options and paid the $4.76 exercise price for each new share. Because the options lapsed unexercised, no such payment occurred and the company received nothing.

Second, the expiry did not materially change the number of ordinary shares on issue. New ordinary shares are created only when options are exercised and converted. Since these options were never exercised, no new shares were issued, and the ordinary share count remained at 196,068,940 fully paid shares. The disappearance of the RACAL options slightly reduces the pool of shares that could theoretically have been created, but does not alter the shares that already trade under ASX: RAC.

Why the market treats this as administrative

Because no cash moved and no shares were created, an Appendix 3H of this kind is treated as an administrative housekeeping notice that keeps the ASX record accurate by removing securities that no longer exist. It is a normal part of the lifecycle of any listed company that has previously issued options, and should not be read as a signal about clinical progress, financial health or share price direction. Racura Oncology continues to hold other unquoted option classes on issue, each following its own terms.

What It Could Mean for ASX: RAC

The most accurate way to frame this development is that it is administrative rather than performance-related. Investors should not interpret the expiry of unexercised options as proof that the business is improving or deteriorating; it is simply the mechanical conclusion of instruments that reached the end of their life.

That said, a modest observation can be made without overreaching. The removal of 270,000 options priced at $4.76 slightly tidies the capital structure by eliminating one small tranche of potential future dilution, the additional shares that could enter the market if outstanding options were exercised. The effect is minor, however, in the context of 196,068,940 ordinary shares already on issue and the several other unquoted option classes that Racura Oncology still carries.

For most shareholders, the practical takeaway is that their existing holdings are unaffected in number. The filing changes the register, not the business.

Limitations and Key Risks

While this event is immaterial to Racura Oncology's operations, the company remains an early to mid-stage biotechnology investment that carries substantial risk, and readers should keep the broader picture in view.

Clinical risk is significant. Racura's programs span a Phase 3 AML study and two Phase 1a/b trials, and clinical trials at any stage can fail to demonstrate the safety or efficacy required to advance; early signals do not guarantee later success. Regulatory risk follows closely, as therapies must satisfy demanding authorities before they can be marketed, and there is no certainty that approvals will be granted or granted on time.

Funding risk is also relevant. Clinical-stage biopharmaceutical companies typically consume cash as they run trials, and this options expiry notably did not raise any capital. Future funding may need to come from other sources, which could include capital raisings that dilute existing shareholders. Execution risk arises from running multiple trials across several countries and collaborators at once. Commercialisation risk remains even if a therapy succeeds clinically, because the company has stated only that it is exploring partnerships, licences and merger and acquisition opportunities, with nothing signed. The Appendix 3H event itself neither adds to nor subtracts from these risks.

What Investors May Watch Next

Investors following Racura Oncology are more likely to find meaningful signals in the company's clinical and corporate calendar than in administrative filings. The company has an investor briefing scheduled in Auckland, New Zealand, and Executive Chair Dr Peter Smith is set to present at and chair sessions at the 20th Bioshares Biotech Summit in Queenstown. Racura's CPACS abstract has also been accepted for a poster presentation at the Global Cardio-Oncology Summit 2026 in Williamsburg, Virginia, in October.

On the capital-structure front, Racura retains several other unquoted option classes on issue, each with its own exercise price and expiry. Should any be exercised, the company would issue new shares and receive the exercise proceeds, reported through the usual ASX channels. Conversely, if further tranches expire unexercised, additional Appendix 3H notices may appear, again as routine housekeeping. Progress across the Phase 3 AML, HARNESS-1 and CPACS programs will remain the more substantive focus for those assessing the ASX: RAC story.

Conclusion

The expiry of 270,000 RACAL options and the resulting Appendix 3H lodged by Racura Oncology Limited (ASX: RAC) is best understood as capital-structure housekeeping. The options reached their 12 July 2026 expiry at an exercise price of $4.76, were never exercised or converted, and ceased without any consideration being paid. No cash was raised and no new shares were created, leaving the company with 196,068,940 ordinary fully paid shares on issue and a RACAL balance of zero. For Racura Oncology, the substance of the investment case continues to rest on the clinical progress of RC220 across its three oncology programs, not on this routine administrative update.